Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 5 studies | 30% ± 10% | |
CD4-positive, alpha-beta T cell | 4 studies | 44% ± 10% | |
ciliated cell | 3 studies | 20% ± 3% | |
epithelial cell | 3 studies | 30% ± 8% | |
erythroblast | 3 studies | 42% ± 23% | |
erythrocyte | 3 studies | 34% ± 16% | |
B cell | 3 studies | 21% ± 2% | |
natural killer cell | 3 studies | 25% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 36% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 97% | 229.65 | 940 / 966 | 98% | 51.48 | 515 / 527 |
skin | 95% | 464.45 | 1716 / 1809 | 96% | 42.35 | 452 / 472 |
bladder | 90% | 105.43 | 19 / 21 | 97% | 50.48 | 490 / 504 |
esophagus | 88% | 198.66 | 1266 / 1445 | 99% | 47.70 | 181 / 183 |
lung | 83% | 136.31 | 478 / 578 | 95% | 48.02 | 1097 / 1155 |
uterus | 77% | 110.33 | 131 / 170 | 100% | 74.87 | 458 / 459 |
stomach | 72% | 124.94 | 257 / 359 | 98% | 48.68 | 281 / 286 |
adrenal gland | 88% | 144.25 | 228 / 258 | 77% | 20.67 | 177 / 230 |
breast | 64% | 63.18 | 293 / 459 | 96% | 52.85 | 1077 / 1118 |
brain | 95% | 311.26 | 2510 / 2642 | 64% | 21.39 | 450 / 705 |
ovary | 23% | 25.09 | 41 / 180 | 99% | 54.95 | 426 / 430 |
prostate | 81% | 95.84 | 199 / 245 | 35% | 5.70 | 174 / 502 |
thymus | 73% | 67.06 | 479 / 653 | 31% | 11.59 | 186 / 605 |
kidney | 85% | 109.49 | 76 / 89 | 18% | 3.17 | 162 / 901 |
lymph node | 0% | 0 | 0 / 0 | 100% | 62.81 | 29 / 29 |
spleen | 100% | 265.22 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 67.30 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 41.72 | 1 / 1 |
muscle | 96% | 259.57 | 772 / 803 | 0% | 0 | 0 / 0 |
liver | 29% | 49.69 | 65 / 226 | 65% | 15.98 | 264 / 406 |
heart | 93% | 250.00 | 802 / 861 | 0% | 0 | 0 / 0 |
pancreas | 6% | 6.09 | 21 / 328 | 86% | 20.46 | 153 / 178 |
adipose | 55% | 53.14 | 668 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 53% | 532.46 | 494 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 44% | 40.27 | 586 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 4.68 | 25 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006281 | Biological process | DNA repair |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0006974 | Biological process | DNA damage response |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0044314 | Biological process | protein K27-linked ubiquitination |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0035519 | Biological process | protein K29-linked ubiquitination |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0085020 | Biological process | protein K6-linked ubiquitination |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003682 | Molecular function | chromatin binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2T |
Protein name | Ubiquitin conjugating enzyme E2 T (Ubiquitin-conjugating enzyme E2T (Putative), isoform CRA_c) Ubiquitin conjugating enzyme E2 T Ubiquitin conjugating enzyme E2 T (Ubiquitin-conjugating enzyme E2T (Putative), isoform CRA_d) Ubiquitin-conjugating enzyme E2 T (EC 2.3.2.23) (Cell proliferation-inducing gene 50 protein) (E2 ubiquitin-conjugating enzyme T) (Ubiquitin carrier protein T) (Ubiquitin-protein ligase T) |
Synonyms | PIG50 hCG_2027327 HSPC150 |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway . Also mediates monoubiquitination of FANCL and FANCI . May contribute to ubiquitination and degradation of BRCA1 . In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination . . |
Accessions | ENST00000646651.1 ENST00000699429.1 ENST00000699423.1 A0A8V8TN93 ENST00000699425.1 A0A8V8TNE2 A0A8V8TQ15 ENST00000699424.1 A0A8V8TPM9 Q9NPD8 A0A2R8Y812 ENST00000643045.1 ENST00000699428.1 |